Perpetual Raises $8 Million in Seed Financing for AI Discovery of Novel Peptides

Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery. The company plans to build a next-gen peptide drug discovery engine using the predictive power of computational physics methods and AI technologies combined with advanced synthetic chemistry. The platform will access what Perpetual calls the “vast, unexplored peptide chemical space.” Perpetual believes its platform will address previously undruggable targets. It said the seed financing would be enough to advance its candidates to clinical stage while building a preclinical portfolio in oncology, autoimmunity and metabolic indications. More details....

Share this with colleagues: